Invuity, Inc., a surgical photonic company based in San Francisco, California, is launching what it calls a “drop in” light to be used in minimal access surgery. Called the Invuity Waveguide XT System, the new product adds to the company’s photonics-based portfolio.
Invuity Throws Light on Minimal Access Surgery

According to the company release, Invuity’s photonics technology delivers visualization of tissue planes, critical structures and anatomical landmarks. An estimated 30% to 40% of all surgical procedures in the United States are minimal access and the percentage is growing, say company officials. They note that minimal access techniques improve surgical outcomes, minimize risks associated with traditional open surgery, and reduce post-operative recovery and hospitalization time.
The surgeon does have to be able to see what he is doing. Proponents of Invuity’s Waveguide XT System report that it can be strategically placed within the incision to direct and shape the illumination deep into the disc space providing startlingly clear visualization without the risk of thermal tissue damage. Warren F. Neely, M.D., Neurosurgery, Christus Santa Rosa Health System in San Antonio, Texas said, “With this innovative drop-in device, surgeons benefit from superior visualization without altering their standard surgical technique or instrumentation.”
Company officials say the technology projects thermally cool, brilliant light to volumetrically illuminate deep surgical cavities, providing visualization while virtually eliminating shadows, glare and thermal hazards.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.